GLP Non responder's

Here2Learn

Member
I’ve been reading studies on GLP’s and found this interesting. Just data points. I read another one saying those who are sicker or had early childhood obesity or trauma had higher rates of non response too.

Quote from study
“Conclusions
A high HbA1c at baseline and previous non-insulin therapy were the main predictors of a greater response (optimal HbA1c and weight response) to GLP1ra in both men and women. This may aid in treatment decision-making before initiating treatment with GLP-1RAs.”

 
I was actually going to ignore you but now you're just lying and spreading misinformation which isn't okay.

The 16mg Mazdutide study was Phase 1, but research on higher doses wasn't stopped, it was finished. They just presented their findings at a conference this September and concluded that it was as safe as other incretin memetics in their phase 1 trials at that dose. Innovent only bothered to investigate the 16mg dose because back in 2023 they found the 9mg dose safe and effective as well.

As for weight loss, I don't know how you do math, but 24.2% weight loss in 48 weeks is slower than 15.4% in 24 weeks or 20.6% in 20 weeks.

If you happen to be anti-Mazdutide because you're worried about your LLY stock, you should know that Eli Lilly owns the rights to Mazdutide everywhere but China because they bought them from Innovent.

View attachment 307471
When the graphic was originally posted, the study was not yet published.

Bhattachar, et al. (pre-publication, 2025-08-20). Mazdutide reduces body weight in adults with overweight or obesity - A high-dose Phase 1 trial. Diabetes Obesity & Metabolism
 
Back
Top